Methicillin-resistant Staphylococcus Aureus Therapeutics Pipeline Analysis 2018
Explore report sample at: https://www.psmarketresearch.com/market-analysis/mrsa-therapeutics-pipeline/report-sample
According to the research findings, a majority of the drug candidates for the treatment of MRSA are being developed to be administered by the intravenous route which offers good bioavailability and is considered to be more effective at the target site.
It has been observed that most of the companies are developing drug candidates with novel mechanism of action. Also, the drug candidates have showed positive efficacy in the clinical as well as Pre-Clinical stage of development. For instance, GlaxoSmithKline plc is developing a Phase II drug candidate, GSK 2140944 or Gepotidacin. It is an intravenous, synthetic, Type II topoisomerase inhibitor. If GSK2140944 hits the market, it would be the first topoisomerase inhibitor for gram-negative infections. Savara Pharma's AeroVanc is the first inhaled antibiotic being developed and is in the Phase III stage of clinical trial and has received $5 million fund from Nonprofit Cystic Fibrosis Foundation. If the drug receives the approval, it would be the first inhaled antibiotic to be developed for the treatment of MRSA.
Browse report at: https://www.psmarketresearch.com/market-analysis/mrsa-therapeutics-pipeline
Some of the key players involved in the development of MRSA therapeutics include GlaxoSmithKline plc, Crystal Genomics Inc., and Innovation Pharmaceuticals Inc.
About P&S Intelligence
P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.
Toll-free: +1-888-778-7886 (USA/Canada)
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Methicillin-resistant Staphylococcus Aureus Therapeutics Pipeline Analysis 2018 here
News-ID: 1233616 • Views: 319
More Releases from P&S Intelligence - Pharmaceuticals
Cyclin-Dependent Kinase Inhibitors Therapeutics Key Players Analysis - Merck, El …
The study analyzed that the CDK inhibitors therapeutics pipeline comprises approximately 24 drug candidates in different stages of development. CDKs are the catalytic subunits of serine or threonine protein kinases that regulate the checkpoints in the cell cycle to control the proliferative capacity of cancerous cells. These proteins form cyclin-CDK complex which gets activated after phosphorylation, leading to cell proliferation. Download report sample at: http://bit.ly/2eqiPu5 **Various collaborations for CDK inhibitors drug development Eli Lilly
Systemic Lupus Erythematosus Pipeline Analysis - Anthera Pharmaceuticals, Inc., …
The study analyzed that the systemic lupus erythematosus pipeline comprises of 57 drug candidates in different stages of development. Explore report sample at: https://www.psmarketresearch.com/market-analysis/systemic-lupus-erythematosus-pipeline-analysis/report-sample Systemic lupus erythematosus is a type of lupus in which the immune system damages its own tissues. The disease affects many parts of the body including skin, joints, lungs, brain, blood vessels and kidneys. The systemic lupus erythematosus is caused by impaired immune system due to which the
Herpes Simplex Virus Infections Therapeutic - Pipeline Analysis, Clinical Trials …
The study analysed that the Herpes simplex virus infections pipeline comprises of 20 drug candidates in different stages of development. As per the findings of the research, most of the drug candidates are being developed to be administered by oral route. Explore report sample at: https://www.psmarketresearch.com/market-analysis/hsv-infections-therapeutics-pipeline-analysis/report-sample Many technologies are being developed that offer promising innovative treatments which can control the progression of Herpes simplex virus infections. The technologies include, but not limited to,
Japanese Encephalitis Therapeutics - Pipeline Analysis, Clinical Trials, Patent …
Japanese encephalitis is a viral infection that spreads by mosquito bites. The study analyzed that the Japanese encephalitis therapeutics pipeline comprises approximately 12 drug candidates in different stages of development. Explore report sample at: https://www.psmarketresearch.com/market-analysis/japanese-encephalitis-therapeutics-pipeline/report-sample The companies developing drugs for the treatment of Japanese encephalitis are laying more emphasis on the drug candidates to be developed as vaccines, due to the promising results shown by these candidates the in the clinical development.
More Releases for MRSA
MRSA Antibiotics Global Industry Report - History, Present and Future 2025
The global market size of MRSA Antibiotics is $XX million in 2017 with XX CAGR from 2013 to 2017, and it is expected to reach $XX million by the end of 2023 with a CAGR of XX% from 2018 to 2023. There are 3 key segments covered in this report: geography segment, end use/application segment and competitor segment. For geography segment, regional supply, application-wise and type-wise demand, major players, price is presented
Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market – Driver
Methicillin-Resistant Staphylococcus Aureus (MRSA) is a type of staphylococcus aureus, which became resistant to methicillin, amoxicillin, penicillin, oxacillin, and other such commonly used antibiotics. Staphylococcus aureus harbors on the skin and nasal passage of about one third of the world population, which comprises around 33%, as per Centers for Disease Control and Prevention (CDC) review 2015. MRSA can be classified into two types, based on mode of infection – Hospital
Global MRSA Testing Devices Market Highlights and Challenges 2017
Qyresearchreports include new market research report "Global MRSA Testing Devices Market Professional Survey Report 2017" to its huge collection of research reports. The global MRSA Testing Devices market has been elaborately studied, researched and detailed on in this publication by taking the assistance of advanced secondary and primary research that has been performed by the best of analysts and by making use of the best of the available techniques. The said
Global MRSA Antibiotics Market: Scenario 2025
“Global MRSA Antibiotics Industry Report" is an expert and in-depth analysis of key business and future development prospects, key determinants and restrictions, profiles of major market players, segmentation and forecasting. The study offers a comprehensive qualitative analysis of the industry's growth parameters, the current state of the market in terms of analysis of key economic situations and macroeconomic analysis. The analysis highlights the growth opportunities of key market segments along
MRSA Testing Devices Market
The global market has been prognosticated to earn demand from popular types of products such as external use, oral and applications such as household and hospital. The Company has made available another publication in its Healthcare archive of market intelligence reports, which is titled “Global MRSA Testing Devices Market Research Report 2018.” While the threat of substitutes and technological risks could have an unfavorable impact on the global market, potential
MRSA Drugs Market 2022: Industry Trend, Growth & Global Forecast
MRSA Drugs Market Analysis, by Drug Origin (semisynthetic and synthetic drugs), by Drug Class, By Key Companies (Allergan, Plc, Merck Inc, Pfizer, Savara Pharmaceuticals, Sealife Pharma) - Forecast to 2022 Market Synopsis of MRSA Drugs Market: Market Scenario: Global MRSA Drugs Market is expected to reach USD 3.1 Billion by the end of the forecasted period from 2016 to 2022; it is confidently expected that this market has a bright future. Most MRSA infections